Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE: NKTR-255 and Durvalumab in NSCLC
NCT05632809Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of NKTR-255 in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2023; status: recruiting.
02
Drugs
NKTR-255
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05632809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632809.